CN106414552B - 制备用于细胞培养基中的泊洛沙姆的方法 - Google Patents

制备用于细胞培养基中的泊洛沙姆的方法 Download PDF

Info

Publication number
CN106414552B
CN106414552B CN201580026701.5A CN201580026701A CN106414552B CN 106414552 B CN106414552 B CN 106414552B CN 201580026701 A CN201580026701 A CN 201580026701A CN 106414552 B CN106414552 B CN 106414552B
Authority
CN
China
Prior art keywords
poloxamer
minutes
cell culture
cell
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580026701.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN106414552A (zh
Inventor
G·P·维瑟维斯瓦兰
R·D·基斯
S·J·迈耶
I·权
K·卡尔霍恩
K·温彻斯特
A·亚当斯
M·格伦
S·凯尼格
A·德泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN202010723304.6A priority Critical patent/CN111808276A/zh
Publication of CN106414552A publication Critical patent/CN106414552A/zh
Application granted granted Critical
Publication of CN106414552B publication Critical patent/CN106414552B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/30—Post-polymerisation treatment, e.g. recovery, purification, drying
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/50—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing nitrogen, e.g. polyetheramines or Jeffamines(r)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/58—Ethylene oxide or propylene oxide copolymers, e.g. pluronics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN201580026701.5A 2014-03-25 2015-03-25 制备用于细胞培养基中的泊洛沙姆的方法 Active CN106414552B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010723304.6A CN111808276A (zh) 2014-03-25 2015-03-25 制备用于细胞培养基中的泊洛沙姆的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461970281P 2014-03-25 2014-03-25
US61/970,281 2014-03-25
PCT/US2015/022592 WO2015148736A1 (en) 2014-03-25 2015-03-25 Methods of preparing a poloxamer for use in cell culture medium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010723304.6A Division CN111808276A (zh) 2014-03-25 2015-03-25 制备用于细胞培养基中的泊洛沙姆的方法

Publications (2)

Publication Number Publication Date
CN106414552A CN106414552A (zh) 2017-02-15
CN106414552B true CN106414552B (zh) 2020-08-25

Family

ID=52824596

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580026701.5A Active CN106414552B (zh) 2014-03-25 2015-03-25 制备用于细胞培养基中的泊洛沙姆的方法
CN202010723304.6A Pending CN111808276A (zh) 2014-03-25 2015-03-25 制备用于细胞培养基中的泊洛沙姆的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010723304.6A Pending CN111808276A (zh) 2014-03-25 2015-03-25 制备用于细胞培养基中的泊洛沙姆的方法

Country Status (19)

Country Link
US (2) US11034793B2 (enExample)
EP (2) EP3778702B1 (enExample)
JP (3) JP6655548B2 (enExample)
KR (1) KR102352250B1 (enExample)
CN (2) CN106414552B (enExample)
AU (1) AU2015236008B2 (enExample)
BR (1) BR112016021739B1 (enExample)
CA (1) CA2943357C (enExample)
ES (1) ES2778680T3 (enExample)
HR (1) HRP20200372T1 (enExample)
IL (2) IL247902B (enExample)
MX (2) MX2016012288A (enExample)
MY (1) MY178060A (enExample)
PL (1) PL3122799T3 (enExample)
RU (1) RU2710551C2 (enExample)
SG (1) SG11201607929PA (enExample)
SI (1) SI3122799T1 (enExample)
WO (1) WO2015148736A1 (enExample)
ZA (1) ZA201606711B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106414552B (zh) 2014-03-25 2020-08-25 豪夫迈·罗氏有限公司 制备用于细胞培养基中的泊洛沙姆的方法
JP7037495B2 (ja) * 2016-03-17 2022-03-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ポロキサマーを精製するための方法
KR102544922B1 (ko) * 2017-12-21 2023-06-16 시그마-알드리치 컴퍼니., 엘엘씨 폴록사머 조성물 및 이의 제조 및 사용 방법
RU2741710C1 (ru) * 2018-07-12 2021-01-28 Елена Валентиновна Аршинцева Термический способ стерилизации жидких лекарственных средств, содержащих в своем составе полоксамер
JPWO2020022511A1 (ja) * 2018-07-27 2021-08-02 味の素株式会社 動物細胞の浮遊培養用の添加物、浮遊培養用培地および浮遊培養方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071452A2 (en) * 2003-02-12 2004-08-26 Ceremed, Inc. Random and non-random alkylene oxide polymer alloy compositions
EP1661558A1 (en) * 2004-11-30 2006-05-31 Basf Aktiengesellschaft Compositions based on micro-prilled poloxamer particles and methods for their manufacturing
CN101910408A (zh) * 2007-12-27 2010-12-08 巴克斯特国际公司 细胞培养方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266710C (enExample)
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
AU632065B2 (en) * 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
FI941538A7 (fi) 1991-10-04 1994-05-31 Gs Dev Ab Partikkelit, menetelmä niiden valmistamiseksi ja niiden käyttö
DK0754050T3 (da) * 1994-01-14 2002-10-21 Xoma Technology Ltd Anti-gram-positive bakterielle fremgangsmåder og materialer
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
GB9625175D0 (en) * 1996-12-04 1997-01-22 Medi Cult As Serum-free cell culture media
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US8802116B2 (en) * 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
AU2003900887A0 (en) * 2003-02-27 2003-03-13 Novasel Australia Pty Ltd Poloxamer emulsion preparations
WO2005014163A1 (en) 2003-08-04 2005-02-17 Camurus Ab Method for loading amphiphile particles with active agents
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2006044738A2 (en) 2004-10-18 2006-04-27 Maroon Biotech Corporation Methods and compositions for treatment of free radical injury
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
EP2054040B1 (en) * 2006-08-16 2011-03-30 Novartis AG Method for making solid dispersions of midostaurin
KR100932613B1 (ko) 2007-04-27 2009-12-17 한남대학교 산학협력단 고분자 용융공정을 이용한 약물전달용 생체적합성 고분자나노 미립구의 제조방법 및 그 나노 미립구
WO2009055312A1 (en) * 2007-10-22 2009-04-30 Dfb Pharmaceuticals, Inc. Process for producing a poloxamer gel
MX2012007117A (es) * 2009-12-23 2012-07-23 Sanofi Pasteur Metodo para cultivar celulas adherentes.
JP6177873B2 (ja) * 2012-03-30 2017-08-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ミクロスフィア組成物、その調製方法及び用途
CN106414552B (zh) * 2014-03-25 2020-08-25 豪夫迈·罗氏有限公司 制备用于细胞培养基中的泊洛沙姆的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071452A2 (en) * 2003-02-12 2004-08-26 Ceremed, Inc. Random and non-random alkylene oxide polymer alloy compositions
EP1661558A1 (en) * 2004-11-30 2006-05-31 Basf Aktiengesellschaft Compositions based on micro-prilled poloxamer particles and methods for their manufacturing
CN101910408A (zh) * 2007-12-27 2010-12-08 巴克斯特国际公司 细胞培养方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Enhanced anti-tumor activity and alleviated hepatotoxicity of clotrimazole-loaded suppository using poloxamer-propylene glycol gel";Chul Soon Yong et al;《International Journal of Pharmaceutics》;20060914;第321卷(第1-2期);第56-61页 *

Also Published As

Publication number Publication date
MX2016012288A (es) 2017-01-23
JP2023011566A (ja) 2023-01-24
IL247902A0 (en) 2016-11-30
CA2943357C (en) 2023-06-27
RU2016141568A3 (enExample) 2018-09-26
AU2015236008A1 (en) 2016-10-27
BR112016021739B1 (pt) 2021-11-03
JP2017516459A (ja) 2017-06-22
ES2778680T3 (es) 2020-08-11
CA2943357A1 (en) 2015-10-01
SI3122799T1 (sl) 2020-06-30
ZA201606711B (en) 2019-12-18
MX2021001981A (es) 2021-04-28
RU2016141568A (ru) 2018-04-28
KR20160138161A (ko) 2016-12-02
US11034793B2 (en) 2021-06-15
JP7472222B2 (ja) 2024-04-22
EP3778702B1 (en) 2023-06-28
JP6655548B2 (ja) 2020-02-26
CN111808276A (zh) 2020-10-23
AU2015236008B2 (en) 2018-12-20
US20170009015A1 (en) 2017-01-12
US20210371587A1 (en) 2021-12-02
EP3778702A1 (en) 2021-02-17
EP3122799B1 (en) 2020-01-15
JP2020103290A (ja) 2020-07-09
BR112016021739A2 (pt) 2017-08-15
WO2015148736A1 (en) 2015-10-01
EP3122799A1 (en) 2017-02-01
IL279583A (en) 2021-03-01
US11912823B2 (en) 2024-02-27
NZ725151A (en) 2021-05-28
SG11201607929PA (en) 2016-10-28
CN106414552A (zh) 2017-02-15
PL3122799T3 (pl) 2020-06-29
WO2015148736A8 (en) 2016-08-18
HRP20200372T1 (hr) 2020-06-12
IL279583B (en) 2022-03-01
KR102352250B1 (ko) 2022-01-17
IL247902B (en) 2021-01-31
EP3122799B8 (en) 2020-03-11
RU2710551C2 (ru) 2019-12-27
MY178060A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
JP7472222B2 (ja) 細胞培養培地における使用のためのポロキサマーを調製する方法
JP7377316B2 (ja) 哺乳類細胞培養物を回収するための方法
KR102235452B1 (ko) 항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법
JP7075927B2 (ja) 緩衝剤溶液を提供するための方法及びシステム
BR122020021864B1 (pt) Meio para cultura de células
CN118995660A (zh) 突变型piggyBac转座酶
JP2011500054A (ja) 安定な保存用中間体を使用した生物製剤の製造方法
TWI736071B (zh) 於蛋白質溶液中控制雙硫鍵形成之方法
HK40038241A (en) Methods of preparing a poloxamer for use in cell culture medium
HK1233287B (zh) 制备用於细胞培养基中的泊洛沙姆的方法
NZ725151B2 (en) Methods of preparing a poloxamer for use in cell culture medium
HK1233287A1 (en) Methods of preparing a poloxamer for use in cell culture medium
HK40008326A (en) Method and system for providing buffer solutions
HK40064109A (en) Serum-free cell culture medium

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1233287

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant